Рынок обнаружения и диагностики генов CRISPR в Северной Америке – тенденции отрасли и прогноз до 2029 года

Определение рынка и его понимание

CRISPR — это кластеризованные, регулярно расположенные короткие палиндромные повторы, инструмент для редактирования генома, позволяющий исследователям легко изменять последовательности ДНК и модифицировать функцию генов. Он имеет множество потенциальных применений, включая исправление генетических дефектов, лечение и профилактику распространения заболеваний. Диагностика на основе CRISPR использовалась для многих биомедицинских приложений, таких как обнаружение биомаркеров инфекционных и неинфекционных заболеваний на основе нуклеиновых кислот и обнаружение генетических заболеваний. Наборы для анализа в CRISPR состоят из двух компонентов: белка Cas9 и направляющей РНК, цепочки молекул нуклеиновых кислот с определенным генетическим кодом.

Эта система CRISPR-Cas9 была модифицирована для использования в клетках млекопитающих. Мы можем либо выбить определенные гены, введя направляющую последовательность (sgRNA), специфичную для нашего интересующего гена, введя мутации сдвига рамки считывания посредством негомологичного соединения концов (NHEJ), либо сгенерировать мутации knock-in.

Системы CRISPR-Cas 9 расширили сферу диагностики и услуг в области генной и клеточной терапии. Фармацевтические компании вкладывают значительные средства в НИОКР для разработки новых продуктов, при этом всплеск генных и клеточных терапевтических агентов выходит на раннюю стадию разработки. Инвестиции участников рынка позволят производить безопасные и эффективные методы лечения для пациентов, которым это действительно необходимо.

Североамериканское обнаружение и диагностика гена CRISPR является поддерживающим и направлено на снижение тяжести симптомов. Data Bridge Market Research анализирует, что рынок обнаружения и диагностики гена CRISPR будет расти в среднем на 19,6% в течение прогнозируемого периода с 2022 по 2029 год.

 North America CRISPR Gene Detection and Diagnostic Market Dynamics

Drivers

• Rise in prevalence and incidence of chronic diseases

Chronic diseases are common health conditions, where one in three the adults suffer from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens.

CRISPR is abbreviated as clustered regularly interspaced short palindromic repeats. In recent years, CRISPR has become a commanding tool for gene editing, which is used to alter the specific sequences of DNA in a cell. CRISPR has important use in the research and treatment of Huntington’s disease, muscular dystrophy, cancer and high cholesterol.

For instance,

• In 2021, the data by NORD - National Organization for Rare Disorders, Inc. stated the diagnosed incidence of Duchenne Muscular Dystrophy (DMD). The Duchenne Muscular Dystrophy (DMD) is a frequent genetic condition, which affects 1 in 3,500 male births worldwide
• Rise In Investment In Research And Development

Gene editing technologies, such as the CRISPR-Cas 9 system, have extended the scope of diagnostics and services in gene and cell therapies. Pharmaceutical companies invest heavily in R&D to develop new products, with a surge of gene and cell therapy agents entering early development. The market players investing would allow to achieve the goal of producing safe and effective treatments for patients in serious need.

For instance,

• In February 2022, Synthego had raised USD 200 million as an investment for research and development to boost the development of CRISPR-Based Medicines from early-phase research to the clinic. Synthego will use the investment amount from Series E finance to accelerate the creation of CRISPR diagnostics and services

Availability of funding for CRISPR gene diagnostics

CRISPR gene diagnostics and research are funded by the National Institute of Health (NIH) budget. The private sector also funds the CRISPR gene detection and research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With genome editing being such a new field, an unbiased governmental body must supervise them; the FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries., will further enhance the growth of the CRISPR gene detection and diagnostic market.

Furthermore, advancement in CRISPR gene diagnostics, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the CRISPR gene detection market. Other factors such as increase in the demand for effective therapies and rising awareness about the timely diagnosis and will positively impact the CRISPR gene detection and diagnostic market's growth rate. Additionally, high disposable income, rising number of chronic diseases, changing lifestyle will result in the expansion of the CRISPR gene detection and diagnostic market.

Opportunities

• The rise in healthcare expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

• Strategic initiative by market players

The demand for CRISPR gene detection and diagnosis has increased the demand in the U.S. and owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

• In May 2021, Horizon Discovery Ltd. extended the gene modulation portfolio with the first synthetic single guide RNA and patent pending dcas9 repressor for CRISPR interference in Waltham. The expansion of the portfolio had increased the sales and revenue of the synthetic guide RNA portfolio across the U.S. and the U.K. region and had increased the collaboration with market players

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the CRISPR gene detection and diagnostic market in the forecast period of 2022-2029. Also, high unmet need of current and developments in healthcare technology will escalate the growth rate of the CRISPR gene detection and diagnostic market in future.

Restraints/Challenges

However, high cost of CRISPR diagnostics and risks faced while using the CRISPR diagnostics will impede the growth rate of CRISPR gene detection and diagnostic market. Additionally, the risks incurred while using the MRI devices will hinder the CRISPR gene detection and diagnostic market growth. The lack of skilled expertise and regulations will further challenge the market in the forecast period mentioned above.

• Rise in cost of CRISPR based diagnostics

The vast potential of CRISPR based therapeutics comes with a cost tag. Maximum genome editing therapies require an increased amount of time for development and production, and hence the rise in cost occurs. Besides, the assay kits and medications related to CRISPR gene detection and diagnostic are applicable to large section of population. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend in the future.

For instance,

• In July 2021, according to Integrated DNA Technologies, Inc., the first commercially available CRISPR-based diagnostic assay for SARS-CoV-2 including reverse transcription LAMP (RT-LAMP) as pre-amplification is currently available at USD 30.15 per reaction

The CRISPR gene detection and diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on CRISPR gene detection and diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to a study by Globocan. In 2020, breast cancer had high incidence of cases, around 11.7%, followed by lung cancer which is 11.40%, colorectum cancer which is 10.00%, and cervix uteri and oesophagus cancer having less number of incident cases.

CRISPR gene detection and diagnostic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on the CRISPR Gene Detection and Diagnostic Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

• In August 2020, SHERLOCK BIOSCIENCES announced a collaboration with Dartmouth-Hitchcock Health, to conduct the clinical trial of SHERLOCK Diagnostic Kit for Sars-CoV-2. The kit received emergency approval from the Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).

North America CRISPR Gene Detection and Diagnostic Market Scope

The CRISPR gene detection and diagnostic market is segmented on the basis of six segments: class, products & services, application, workflow, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Class

• Class 1- Multiple Effector Proteins
• Class 2 -Single CrRNA Binding Protein

On the basis of class, the CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single CrRNA binding protein.

Products & Services

• Products
• Services

On the basis of products & services, the CRISPR gene detection and diagnostic market is segmented into products & services.

Application

• Biomedical Diagnostics
• Genome Engineering
• Drug Discovery
• Agricultural Applications
• Others

On the basis of application, the CRISPR gene detection and diagnostic market is segmented into is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others.

Workflow

• Sample Preparation
• Pre-Amplification
• CrRNA
• Cas Enzymes
• Sensing

On the basis of workflow, the CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, CrRNA, Cas enzymes and sensing.

End User

• Hospitals
• Diagnostic Centers
• Biotechnology Companies
• Academic and Research Institutes
• Others

On the basis of end user, the CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others.

Distribution Channel

• Direct Tenders
• Retail Sales

On the basis of distribution channel, the CRISPR gene detection and diagnostic market is segmented into direct tenders and retail sales.

CRISPR Gene Detection and Diagnostic Market Regional Analysis/Insights

The North America CRISPR gene detection and diagnostic market is analysed and market size insights and trends are provided by regions, class, products & services, application, workflow, end user, and distribution channel as referenced above.

The countries covered in the CRISPR gene detection and diagnostic market report are U.S., Canada and Mexico.

The U.S. dominates the CRISPR gene detection and diagnostic market due to the rise in healthcare expenditure.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка внутри страны, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, замещающие продажи, демография страны, эпидемиология заболеваний и импортно-экспортные пошлины, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность брендов Северной Америки и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние каналов продаж.

Конкурентная среда и анализ доли рынка обнаружения и диагностики генов CRISPR

Конкурентная среда рынка обнаружения и диагностики гена CRISPR в Северной Америке содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, присутствие в Северной Америке, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта, доминирование приложений. Приведенные выше данные относятся только к фокусу компаний, связанному с рынком обнаружения и диагностики гена CRISPR.

Некоторые из основных игроков, работающих на рынке обнаружения и диагностики генов CRISPR, включают GenScript, OriGene Technologies, Inc., Applied StemCell, GeneCopoeia, Inc., Agilent Technologies, Inc., Synthego, BioVision Inc., Hera Biolabs, Cellecta, Inc., New England Biolabs, 10x Genomics, addgene CasTag Biosciences, Merck KGaA, Integrated DNA Technologies, Inc. (дочерняя компания Danaher), Thermo Fisher Scientific Inc. и другие.

SKU-68325